
A legal fight over a single amino acid could set retatrutide's exclusivity window, its Medicare negotiation clock, and its competitive future.
Here is a policy briefing for chief medical officers and managed care leaders on key pressure points about the Medicaid funding cuts.
As the One Big Beautiful Bill Act (OBBBA) reshapes federal





